Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

1 In 10 Americans turn to social media for health information

Amid culture wars over masking, Covid-19 treatments, and vaccine mandates, many Americans are at a loss for who to trust when it comes to healthcare information.

With Facebook under new fire for putting profits over people based on a whistleblower’s testimony before Congress, it’s a wonder that anyone trusts social media platforms at all, especially in a healthcare context.

But according to new data released this week from PatientsLikeMe, an online patient community, 11% of Americans surveyed said they turn to social media when looking for reliable health information. Nearly one in ten (9%) also said they use social media to evaluate new treatment options and 7% seek information about medication side effects from social media.

Source: Forbes

https://www.forbes.com/sites/debgordon/2021/10/06/1-in-10-americans-turn-to-social-media-for-health-information-new-survey-shows/?sh=750cd1f3d934

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!